Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System

Reveal LINQ Usability Study

The purpose of the Reveal LINQ Usability Study is to assess the functionality of the Reveal LINQ insertable cardiac monitor and accompanying system in patients indicated for an insertable cardiac monitor

Study Overview

• Status: Completed
• Conditions: Syncope; Recurrent Symptomatic Atrial Fibrillation
• Intervention / Treatment: Device: Insertable Cardiac Monitor Implant

Detailed Description

The Reveal LINQ Usability Study is a prospective, non-blinded, non-randomized, multi-center clinical trial. Subjects will transmit device data via manual interrogation on a weekly basis during the first month and will be evaluated in the office at 1-month post-implant, in addition to an automatic nightly wireless data transmission using the MyCareLink® home monitor. All subjects will be requested to wear an external Holter for 48 hours at approximately 4 weeks post-insertion. Follow-up visits will continue at 6 and 12 months post-implant, with monthly manual interrogations. Subjects will be exited at their 12 month follow-up visit. The overall study will be conducted in 2 phases which differ primarily on inclusion criteria: Phase I subjects (initial 30 subjects) will have any indication for an ICM, Phase II subjects (all subjects following the initial 30 subjects) will be atrial fibrillation (AF) pre-ablation patients. The study will assess functionality of the Reveal LINQ device by assessing sensing performance and data transmission.

• Study Type: Interventional
• Enrollment (Actual): 151
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Australia
  • Queensland
    • Brisbane, Queensland, Australia, 4032
      • The Prince Charles Hospital
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Royal Adelaide Hospital
  • Victoria
    • Melbourne, Victoria, Australia, 3050
      • Royal Melbourne Hospital
• Austria
  • Linz, Austria
    • Allgemeines Krankenhaus der Stadt Linz
  • Linz, Austria
    • Allgemein öffentliches Krankenhaus der Elisabethinen Linz
• Belgium
  • Leuven, Belgium
    • UZ Leuven - Campus Gasthuisberg
  • Yvoir, Belgium
    • CHU UCL Mont-Godinne - Dinant
• Netherlands
  • Eindhoven, Netherlands
    • Catharina Ziekenhuis
  • Maastricht, Netherlands
    • Academisch Ziekenhuis Maastricht
  • Nieuwegein, Netherlands
    • St. Antonius Ziekenhuis - Locatie Nieuwegein
  • Utrecht, Netherlands
    • Diakonessenhuis Locatie Utrecht
  • Zwolle, Netherlands
    • Isala Klinieken - Locatie Weezenlanden
• Russian Federation
  • Novosibirsk, Russian Federation
    • Scientific Research Institute of Circulation's Pathology Agency on High Medical Technologies
• Slovakia
  • Bratislava, Slovakia
    • Narodny ustav srdcovych a cievnych chorob, a.s. (NUSCH)
• United Kingdom
  • Eastbourne, United Kingdom
    • Eastbourne District General Hospital
  • Middlesbrough, United Kingdom
    • James Cook University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is willing to sign and date the consent form.
• Subject is indicated for a Reveal device within the existing market approved indications
• Phase I (initial 30 subjects): Any indication for a Reveal LINQ Device

• Phase II (after the initial 30 subjects): Subject has atrial fibrillation and is indicated for and identified as an AF pre-ablation candidate*

  *Note: Atrial fibrillation must be documented in the subject's medical history.

• Subject has a life expectancy of 18 months or more.
• Subject is willing and able to set up and utilize MyCareLink® home monitor and be remotely monitored (i.e., Medtronic CareLink® Network)
• Subjects who are female of childbearing potential (last menses less than 1 year prior to enrolment) must:
• have a negative pregnancy test at enrollment.
• not be breastfeeding.
• either be surgically sterile, postmenopausal (cessation of menses for at least 1 year), or agree to use a medically accepted, highly effective method of contraception during the entire duration of the study.

Exclusion Criteria:

• Subject has an active implanted cardiac medical device (e.g., IPG, ICD, CRT, etc).
• Subject is unwilling or unable to comply with the study procedures
• Subject is legally incapacitated and unable to provide written informed consent.
• Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological diagnosis)
• Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager.
• Local law prohibits participation (e.g., minor status as specified by local law)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Insertable Cardiac Monitor Implant

Device: Insertable Cardiac Monitor Implant; The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Success of Wireless Transmissions	To assess the percentage of successful automatic wireless transmissions from the system within the first 30 days of implant.	30 days
R-wave Amplitude	To characterize the signal quality of the R-wave amplitude at implant and one month.	30 days
R-wave Amplitudes Greater Than or Equal to 200 μV	The proportion of R-wave amplitudes that are greater than or equal to 200 μV will be estimated at implant and one month.	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Accuracy of Reveal LINQ Device Detected Atrial Fibrillation	To assess atrial fibrillation detection by the Reveal LINQ insertable cardiac monitor (ICM). True and false positives will be reported.	4 months
Safety Endpoint	To characterize the system-related and procedure-related adverse events.	12 months
Accuracy of Device Detected Atrial Fibrillation Compared to Holter Monitor	To compare the Reveal LINQ atrial fibrillation detection accuracy with atrial fibrillation detection from Holter monitoring. The true positive rate (sensitivity), specificity, positive predictive value and negative predictive value will be estimated using Holter recordings as the gold standard. Sensitivity measures the proportion of positives that are correctly identified as such. Specificity measures the proportion of negatives that are correctly identified as such. The positive and negative predictive values are the proportion of positive and negative detected patients that are true positive and true negative, respectively. Accuracy measures the proportion of all patients that are correctly identified as negative or positive.	48 hours
Survey of the Implanting Physicians	To understand the implanting physicians' experience with the implant of the Reveal LINQ, and the accompanying implanter tools. Responses to survey questions will be characterized. Below we summarize the responses to survey question "Overall, how would you rate the ease of entire implant procedure?".	Day of implant
Survey of the Patient Experience Over Time	To understand the study subjects' experience with the Reveal LINQ, the patient assistant and the patient home monitor. Patient responses to survey questions will be characterized. Below we will summarize the responses to question "Based on your experience to date, please rate your satisfaction with the Reveal LINQ device" over 1 month, 6 month, and 12 month follow-up visit.	12 months

Collaborators and Investigators

• Sponsor: Medtronic Cardiac Rhythm and Heart Failure
• Investigators: Principal Investigator: Helmut Pürerfellner, MD, Allgemein öffentliches Krankenhaus der Elisabethinen Linz; Principal Investigator: Lukas Dekker, MD, Catharina Ziekenhuis

Publications and helpful links

General Publications

• Purerfellner H, Sanders P, Pokushalov E, Di Bacco M, Bergemann T, Dekker LR; Reveal LINQ Usability Study Investigators. Miniaturized Reveal LINQ insertable cardiac monitoring system: First-in-human experience. Heart Rhythm. 2015 Jun;12(6):1113-9. doi: 10.1016/j.hrthm.2015.02.030. Epub 2015 Feb 26.

Study record dates

Study Major Dates

• Study Start: September 1, 2013
• Primary Completion (Actual): July 1, 2014
• Study Completion (Actual): September 1, 2015

Study Registration Dates

• First Submitted: October 16, 2013
• First Submitted That Met QC Criteria: October 16, 2013
• First Posted (Estimate): October 18, 2013

Study Record Updates

• Last Update Posted (Estimate): September 23, 2016
• Last Update Submitted That Met QC Criteria: August 2, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Arrhythmias, Cardiac; Unconsciousness; Consciousness Disorders; Atrial Fibrillation; Syncope
• Other Study ID Numbers: Reveal LINQ Usability Study